Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer

J Thorac Cardiovasc Surg. 2022 May;163(5):1685-1692. doi: 10.1016/j.jtcvs.2021.05.053. Epub 2021 Jul 10.

Authors

Gavitt A Woodard¹, Andrew Li², Daniel J Boffa²

Affiliations

¹ Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, Conn. Electronic address: gavitt.woodard@yale.edu.
² Section of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, Conn.

PMID: 34334172
DOI: 10.1016/j.jtcvs.2021.05.053

No abstract available

Keywords: NCCN guidelines; adjuvant therapy; early-stage NSCLC; prognostic markers; treatment recommendations.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / surgery
Chemotherapy, Adjuvant
Combined Modality Therapy
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / surgery
Neoplasm Staging